Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
16 February 1996Website:
http://www.iridex.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:07:42 GMTDividend
Analysts recommendations
Institutional Ownership
IRIX Latest News
Iridex (IRIX) reported a quarterly loss of $0.21 per share, which was higher than the expected loss of $0.12 per share according to the Zacks Consensus Estimate. This is an increase from the loss of $0.13 per share reported a year ago.
IRIDEX Corporation (IRIX) Q4 2023 Earnings Call Transcript
Iridex (IRIX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
MOUNTAIN VIEW, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release financial results for the fourth quarter and full year 2023 and provide an update on its strategic review process after the close of trading on Tuesday, March 26, 2024.
The Company also announced plans to present at Stifel Healthcare Conference The Company also announced plans to present at Stifel Healthcare Conference
MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023.
IRIDEX Corporation (NASDAQ:IRIX ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Philip Taylor - Gilmartin Group David Bruce - President, CEO & Director Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Partners Thomas Stephan - Stifel, Nicolaus & Company Operator Good day, and thank you for standing by. Welcome to the Second Quarter 2023 IRIDEX Earnings Conference Call.
Iridex (IRIX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago.
Iridex (IRIX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.15 per share a year ago.
What type of business is IRIDEX?
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
What sector is IRIDEX in?
IRIDEX is in the Healthcare sector
What industry is IRIDEX in?
IRIDEX is in the Medical Devices industry
What country is IRIDEX from?
IRIDEX is headquartered in United States
When did IRIDEX go public?
IRIDEX initial public offering (IPO) was on 16 February 1996
What is IRIDEX website?
https://www.iridex.com
Is IRIDEX in the S&P 500?
No, IRIDEX is not included in the S&P 500 index
Is IRIDEX in the NASDAQ 100?
No, IRIDEX is not included in the NASDAQ 100 index
Is IRIDEX in the Dow Jones?
No, IRIDEX is not included in the Dow Jones index
When does IRIDEX report earnings?
The next expected earnings date for IRIDEX is 09 August 2024